Genelux Corp (GNLX) — Titan Protect Analysis

GNLX

Genelux Corp

Healthcare · ·

$2.93

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$130M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-3.82

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

N/A

How much profit the company keeps from each dollar of revenue

ROE

-127.3%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$16.00

+446% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 6 analysts covering this stock

About Genelux Corp

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer. It also offers CHOICE, a technology and discovery and development platform; and developed an extensive library of isolated and e

https://www.genelux.com

Country: United States Employees: 25 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

ACCUMULATION

Smart money appears to be building positions quietly

Sharpe Ratio

0.572

Good returns relative to risk taken

Kelly Fraction

0.0184

Marginal edge — very small allocation suggested

Calmar Ratio

0.126

Drawdown risk outweighs the returns — higher risk profile

Annual Return

9.1%

Historical annualised return based on price data

Max Drawdown

-72.1%

Largest peak-to-trough decline — the worst it has been

HMM State

BULL

Statistical model sees bullish momentum

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

N/A

52W High

$8.54

66% below the year high

52W Low

$2.29

28% above the year low

Avg Volume

183,152

Average daily shares traded — higher means easier to buy and sell

Short Ratio

17.0

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.85

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

10.89

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

100.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-432,112.5%

Profit from core operations before interest and tax

Free Cash Flow

$-15,583,625

Negative — the business is spending more than it generates

Revenue (TTM)

$8,000

Total revenue over the last 12 months

Net Income

$-33,581,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$31.00

Target Median

$16.00

Target Low

$10.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go